Skip to content

R&D at other companies

Amgen logo
AmgenAMGN
$1.72B+15.7%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$42.5M-6.6%
Biogen logo
BiogenBIIB
$539M+24.2%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$38.38M-4.1%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$30M+18.6%
Viatris logo
ViatrisVTRS
$248.6M+12.0%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's R&D?
Organon (OGN) reported R&D of $93M in Q1 2026.
How has Organon's R&D changed year-over-year?
Organon's R&D decreased by 3.1% year-over-year, from $96M to $93M.
What is the long-term trend for Organon's R&D?
Over 4 years (2021 to 2025), Organon's R&D has grown at a -4.7% compound annual growth rate (CAGR), from $443M to $366M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.